We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Seattle Genetics has halted all trials of its vadastuximab talirine after a review uncovered a high death rate in acute myeloid leukaemia patients treated with the drug.